What PARI Pharma does

PARI Pharma (legally PARI GmbH) is a privately-held German pharmaceutical technology company founded in 1997, headquartered near Munich (Starnberg), specializing in aerosol delivery devices and comprehensive inhalation drug development. The company operates as a B2B technology partner rather than a drug developer, providing customized nebulizer platforms that pharmaceutical companies integrate with their inhaled drug formulations across clinical development, regulatory submission, and commercial phases.

PARI's core product is the eFlow Technology platform — a proprietary vibrating mesh nebulizer system that generates precisely defined aerosol particles for targeted lung deposition. The platform differentiates on delivery efficiency (~8.5 minutes per dose versus 45-60 minutes on general-purpose nebulizers) and silent operation. It supports biologics (40% of pipeline), nucleotides (20%), and small molecules (40%), with at least three productized variants: eFlow Technology (the platform), eFlow Open System Nebulizer (customized per drug formulation), and Lamira Nebulizer System (the commercial product delivering Insmed's ARIKAYCE). Manufacturing is conducted at two PARI GMP-qualified sites for both clinical and commercial supply. The portfolio includes 20+ undisclosed projects plus disclosed partnerships with Insmed, Savara, Zambon, Avalyn Pharma, Renovion, and ReCode Therapeutics spanning Phase I through NDA-stage development.

The business model is OEM-embedded B2B device supply and customization. PARI generates revenue by manufacturing and supplying customized eFlow nebulizer systems to pharmaceutical partners, supporting them through device customization, regulatory, and usability stages in exchange for device supply agreements. Pricing is not publicly disclosed. The company has no direct consumer product; its economic exposure is fully tethered to the commercial success and lifecycle of its pharmaceutical partners' drug-device combination products. Notable validated commercial traction exists via ARIKAYCE (Insmed, $433.8M drug revenue in 2025), and an NDA-stage asset (Savara's MOLBREEVI, PDUFA November 2026) is approaching potential conversion.

Name

PARI Pharma

Legal name

PARI GmbH

Website

https://paripharma.com

Company type

Private

Founded year

1997

Operating status

Operating

Short description

PARI Pharma (PARI GmbH) is a German pharmaceutical technology partner that develops and manufactures customized eFlow mesh nebulizer systems for pharmaceutical companies' inhaled drug formulations, serving biologic, nucleotide, and small molecule drug developers across clinical and commercial stages.

Ownership category

akta.pro rank

Product category

Inhalation Drug Delivery Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ)

Keywords

• Mesh nebulizer technology
• Inhalation drug delivery
• Aerosol delivery devices
• Pharmaceutical device partnering
• Nebulizer platform customization

Headquarters

HQ city

Starnberg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Nebulizer Device Supply: PARI supplies customized eFlow nebulizer systems to pharmaceutical partners for clinical and commercial use. Revenue likely derives from device manufacturing, customization services, and ongoing supply agreements with pharmaceutical partners developing inhaled therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

PARI Pharma develops and supplies customized eFlow mesh nebulizer systems to pharmaceutical companies for the delivery of inhaled therapies. The company operates as a B2B technology partner, providing device development, regulatory support, and commercial-scale manufacturing across biologics, nucleotides, and small molecule drug programs. Their eFlow vibrating membrane platform enables targeted aerosol delivery to the lungs with reduced treatment times relative to conventional nebulizers.

Product overview

PARI Pharma operates as a specialized nebulizer technology partner for pharmaceutical companies, offering its eFlow Technology platform as the core product for inhalation drug delivery. The portfolio includes the eFlow mesh nebulizer technology (a vibrating membrane-based aerosol delivery system), the eFlow Open System nebulizer for customized drug formulations, and the Lamira Nebulizer System used in commercial products. PARI's platform serves pharmaceutical partners across multiple therapeutic areas including pulmonology, transplant medicine, and rare diseases, with over 20 undisclosed projects in pre-clinical and clinical development spanning biologics (40%), small molecules (40%), and nucleotides (20%).

Differentiator

Problem solved

Functional benefit

Products and services

• eFlow Technology PARI's proprietary high-end mesh nebulizer technology platform for inhalation drug delivery, featuring vibrating membrane technology that produces a precisely defined aerosol cloud with efficient lung deposition. Customized per partner drug formulation for clinical and commercial supply.
• eFlow Open System Nebulizer A customized version of the eFlow mesh nebulizer designed for specific drug formulations, offering approximately 8.5 minutes per dose delivery time compared to 45-60 minutes with general-purpose nebulizers.
• Lamira Nebulizer System PARI's eFlow-based nebulizer system used commercially to deliver ARIKAYCE (amikacin liposome inhalation suspension) for treatment of Mycobacterium avium complex (MAC) lung disease.

Quantifiable outcome

• ~8.5 minutes per dose with eFlow Open System nebulizer vs ~27 DPI inhalations or 45-60 minutes on general-purpose nebulizers

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, major and supporting.

• Insmed IncorporatedcoreTechnology or IntegrationInsmed uses PARI's Lamira Nebulizer System to deliver ARIKAYCE® (Amikacin Liposome Inhalation Suspension) for MAC Lung disease. This is a Phase III label extension partnership. Insmed generates significant revenue ($433.8M in 2025) from ARIKAYCE, demonstrating commercial success of the PARI-delivered product. PARI also mentioned in Insmed's ASPEN trial presentations.
• Savara Inc.coreTechnology or IntegrationSavara is developing MOLBREEVI (molgramostim) delivered via PARI's eFlow Nebulizer System for autoimmune Pulmonary Alveolar Proteinosis (aPAP). The product is at NDA stage with FDA PDUFA date of November 22, 2026. Patent protection secured in Europe (Patent No. 4121000) and Australia through March 2041. Potential first and only approved therapy for this rare lung disease.
• ZambonmajorTechnology or IntegrationZambon is developing L-CsA-I (Inhaled Cyclosporine) for Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation and Inhaled CMS for Non-CF Bronchiectasis, both using PARI's eFlow Technology. Both programs are in Phase III development.
• Avalyn PharmamajorTechnology or IntegrationAvalyn Pharma uses customized eFlow Technology nebulizers for AP01 (inhaled pirfenidone) targeting Progressive Pulmonary Fibrosis. The Phase 2b MIST trial enrolled 375 patients with topline results expected in H2 2027. Avalyn also developing AP02 for Idiopathic Pulmonary Fibrosis using the same platform.
• RenovionsupportingTechnology or IntegrationRenovion is developing ARINA-1 for respiratory conditions using PARI's eFlow Technology at Phase II stage.
• ReCode TherapeuticssupportingTechnology or IntegrationReCode Therapeutics is developing RCT1100 for Primary Ciliary Dyskinesia (PCD) using PARI's eFlow Technology at Phase I stage.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Nemera: Nemera is a drug delivery device company with a dedicated inhalation franchise including nebulizer and related respiratory devices. It serves pharmaceutical partners developing inhaled therapies with custom device solutions, comparable to PARI's OEM-embedded model.
• Kindeva Drug Delivery: Kindeva (formerly 3M Drug Delivery Systems) is a leading CDMO offering formulation and device development services for inhaled pharmaceuticals, including nebulizer, DPI, and pMDI programs. It competes with PARI on partner selection for inhaled drug development projects.
• Aerogen: Aerogen is the leading vibrating mesh nebulizer manufacturer focused on hospital and acute care aerosol drug delivery. It competes most directly with PARI's eFlow platform in the high-performance mesh nebulizer category serving pharmaceutical partners and clinical applications.
• Owen Mumford: Owen Mumford is a drug delivery device manufacturer with capabilities spanning injectors, inhalation, and other delivery routes. It provides custom device development services to pharmaceutical partners in adjacent drug delivery categories to PARI.
• Hovione: Hovione is a contract development and manufacturing organization with strong inhalation drug product capabilities spanning APIs, formulation, and device integration. It offers an alternative integrated platform to pharmaceutical partners developing inhaled therapies.
• Bespak (Recipharm): Bespak, now part of Recipharm, is a specialist in inhalation and nasal drug delivery devices including pMDIs and DPIs. It provides device development and commercial supply services to pharmaceutical partners developing inhaled therapeutics.

Others

• Copley Scientific: Copley Scientific supplies testing equipment and services for inhaler and nebulizer development, including cascade impactors and aerodynamic particle sizing. It serves the same pharmaceutical R&D ecosystem that PARI addresses as an enabling equipment vendor.

Broad incumbents

• Catalent (Novo Holdings): Catalent is a large pharmaceutical services CDMO with inhalation development and manufacturing capabilities. It competes with PARI in offering integrated inhalation drug product services to pharma partners and serves as an alternative development partner.
• Vectura (Philip Morris): Vectura, acquired by Philip Morris International, is a specialist inhalation drug delivery company with DPI and nebulizer device platforms. It serves comparable pharmaceutical partners across the inhaled therapy development pipeline.
• Aptar Pharma: Aptar Pharma is a global leader in drug delivery devices across nasal, pulmonary, ophthalmic, and injectable modalities. It competes broadly in inhalation device development and supply as part of a wider drug delivery portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pari-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PARI Pharma